(Q37519725)

20 August 2017

1 reference

title

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease (English)

1 reference

20 August 2017

0 references

David B Henley

1

1 reference

20 August 2017

Patrick C May

series ordinal

2

1 reference

20 August 2017

Robert A Dean

series ordinal

3

1 reference

20 August 2017

Eric R Siemers

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Opinion on Pharmacotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

10

1 reference

20 August 2017

page(s)

1657-1664

1 reference

The Natural History of Alzheimer's Disease: A Brain Bank Study

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Treatment of Alzheimer's disease with cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Alzheimer disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

New insights into the genetics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Alzheimer's disease: genotypes, phenotypes, and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

New pathways in drug discovery for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Alzhemed: a potential treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903044982

10.1517/14656560903044982

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference